echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The second domestic company: Jiuyuan Gene declares semaglutide biosimilar drug

    The second domestic company: Jiuyuan Gene declares semaglutide biosimilar drug

    • Last Update: 2021-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Text | plus one

    On July 27, the official website of CDE showed that the smeglutide injection of Jiuyuan Gene was applied for clinical application


    Semaglutide is a new long-acting glucagon-like peptide-1 (GLP-1) analogue of Novo Nordisk


    Smeglutide is Novo Nordisk's drug with the highest sales share.


    The CDE patent information registration platform shows that Novo Nordisk's smeglutide sequence structure patent and use patent expire in March 2026 in China


    Nine gene is a member of the company Hangzhou East China Pharmaceutical Group Holdings Limited


    In the field of diabetes, in addition to semaglutide, Huadong Medicine has also deployed the GLP-1 receptor agonist liraglutide.


    However, with Eli Lilly's dual-target hypoglycemic drug Tirzepatide head-to-head phase 3 clinical success of semaglutide, the future hypoglycemic drug market may shift to multi-target hypoglycemic drugs


    In this field, Huadong Medicine has also obtained an early pipeline through introduction + acquisition: In June 2021, it introduced the Japanese SCOHIA PHARMA, Inc.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.